You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Genomic biomarker-based cancer treatments

Entrectinib for treating NTRK fusion-positive solid tumours

  • Technology appraisal guidance
  • Reference number: TA644
  • Published:  12 August 2020
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 123 KB)

    Published:
    12 August 2020
  • Register of interests (PDF 93 KB)

    Published:
    12 August 2020

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 354 KB)

    Published:
    25 June 2020
  • Public committee slides (PDF 1.09 MB)

    Published:
    25 June 2020
  • Committee papers (PDF 8.94 MB)

    Published:
    25 June 2020
  • Final appraisal document Managed Access Agreement (PDF 478 KB)

    Published:
    25 June 2020

Invitation to participate

  • Final scope (PDF 178 KB)

    Published:
    08 March 2019
  • Final stakeholder list (PDF 203 KB)

    Published:
    08 March 2019
  • Draft scope and provisional stakeholder list comments table (post-referral) (PDF 279 KB)

    Published:
    08 March 2019
  • Equality impact assessment (Scoping) (PDF 123 KB)

    Published:
    08 March 2019
  • Final stakeholder list Updated comparators (MSWord 76 KB)

    Published:
    12 August 2019

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Draft scope post referral (PDF 324 KB)

    Published:
    21 November 2018
  • Draft matrix post referral (PDF 277 KB)

    Published:
    21 November 2018
Back to top